Table 5.
Multivariate proportional-hazards regression analysis of cofactors on progression-free survival in glioblastoma patients with conventionally fractionated radiotherapy.
| Cofactors | HR | 95% CI | p value |
|---|---|---|---|
| Karnofsky performance status > 80 | 0.83 | 0.45–1.53 | 0.55 |
| Peripheral versus central | 0.52 | 0.26–1.03 | 0.27 |
| Biopsy versus surgical resection | 0.72 | 0.32–1.60 | 0.42 |
| Temozolomide therapy | 0.78 | 0.40–1.54 | 0.47 |
| Mean IL SVZ dose ≥ 40 Gy | 0.52 | 0.26–1.03 | 0.06 |
| Mean CL SVZ dose ≥ 30 Gy | 0.45 | 0.20–0.98 | 0.04 |
CI: confidence interval; HR: hazard ratio; IL: ipsilateral; CL: contralateral; SVZ: subventricular zone; Gy: gray.